These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16061987)

  • 1. Quantitative evaluation of HIV and SIV co-receptor use with GHOST(3) cell assay.
    Vödrös D; Fenyö EM
    Methods Mol Biol; 2005; 304():333-42. PubMed ID: 16061987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.
    Edinger AL; Hoffman TL; Sharron M; Lee B; O'Dowd B; Doms RW
    Virology; 1998 Sep; 249(2):367-78. PubMed ID: 9791028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative evaluation of HIV-1 coreceptor use in the GHOST3 cell assay.
    Vödrös D; Tscherning-Casper C; Navea L; Schols D; De Clercq E; Fenyö EM
    Virology; 2001 Dec; 291(1):1-11. PubMed ID: 11878871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coreceptor usage of sequential isolates from cynomolgus monkeys experimentally Infected with simian immunodeficiency virus (SIVsm).
    Vödrös D; Thorstensson R; Biberfeld G; Schols D; De Clercq E; Fenyö EM
    Virology; 2001 Dec; 291(1):12-21. PubMed ID: 11878872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the human chemerin receptor--ChemR23/CMKLR1--as co-receptor for human and simian immunodeficiency virus infection, and identification of virus-binding receptor domains.
    Mårtensson UE; Fenyö EM; Olde B; Owman C
    Virology; 2006 Nov; 355(1):6-17. PubMed ID: 16904155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plaque-reduction assays for human and simian immunodeficiency virus neutralization.
    Nordqvist A; Fenyö EM
    Methods Mol Biol; 2005; 304():273-85. PubMed ID: 16061983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coreceptor usage of BOB/GPR15 and Bonzo/STRL33 by primary isolates of human immunodeficiency virus type 1.
    P Hlmann S; Krumbiegel M; Kirchhoff F
    J Gen Virol; 1999 May; 80 ( Pt 5)():1241-1251. PubMed ID: 10355771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.
    Blaak H; Boers PH; Gruters RA; Schuitemaker H; van der Ende ME; Osterhaus AD
    J Virol; 2005 Feb; 79(3):1686-700. PubMed ID: 15650194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models.
    Unutmaz D; KewalRamani VN; Littman DR
    Semin Immunol; 1998 Jun; 10(3):225-36. PubMed ID: 9653049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A CXC chemokine receptor, CXCR5/BLR1, is a novel and specific coreceptor for human immunodeficiency virus type 2.
    Kanbe K; Shimizu N; Soda Y; Takagishi K; Hoshino H
    Virology; 1999 Dec; 265(2):264-73. PubMed ID: 10600598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the alternative coreceptor GPR15 in SIV tropism for human cells.
    Kiene M; Marzi A; Urbanczyk A; Bertram S; Fisch T; Nehlmeier I; Gnirss K; Karsten CB; Palesch D; Münch J; Chiodi F; Pöhlmann S; Steffen I
    Virology; 2012 Nov; 433(1):73-84. PubMed ID: 22874069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV.
    Shimizu N; Tanaka A; Oue A; Mori T; Ohtsuki T; Apichartpiyakul C; Uchiumi H; Nojima Y; Hoshino H
    AIDS; 2009 Apr; 23(7):761-9. PubMed ID: 19307942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.
    Owen SM; Masciotra S; Novembre F; Yee J; Switzer WM; Ostyula M; Lal RB
    J Virol; 2000 Jun; 74(12):5702-8. PubMed ID: 10823878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and coreceptor activity of STRL33/Bonzo on primary peripheral blood lymphocytes.
    Sharron M; Pöhlmann S; Price K; Lolis E; Tsang M; Kirchhoff F; Doms RW; Lee B
    Blood; 2000 Jul; 96(1):41-9. PubMed ID: 10891428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of CCR5 on activated CD4 T cells in HIV-infected Indians.
    Dubey S; Khalid M; Wesley C; Khan SA; Wanchu A; Jameel S
    J Clin Virol; 2008 Sep; 43(1):25-31. PubMed ID: 18462992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line.
    Soda Y; Shimizu N; Jinno A; Liu HY; Kanbe K; Kitamura T; Hoshino H
    Biochem Biophys Res Commun; 1999 May; 258(2):313-21. PubMed ID: 10329384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coreceptor-dependent inhibition of the cell fusion activity of simian immunodeficiency virus Env proteins.
    Yang C; Yang Q; Compans RW
    J Virol; 2000 Jul; 74(13):6217-22. PubMed ID: 10846110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and sequencing of cynomolgus macaque CCR3, GPR15, and STRL33: potential coreceptors for HIV type 1, HIV type 2, and SIV.
    Wade-Evans AM; Russell J; Jenkins A; Javan C
    AIDS Res Hum Retroviruses; 2001 Mar; 17(4):371-5. PubMed ID: 11242524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new SIV co-receptor, STRL33.
    Alkhatib G; Liao F; Berger EA; Farber JM; Peden KW
    Nature; 1997 Jul; 388(6639):238. PubMed ID: 9230431
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
    Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
    Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.